Table 3.
Table showing the studies using metronomic regimens in ovarian cancer. Bev, Bevacizumab; CP, Cyclophosphamide.
| Author | Treatment | N | Patient type | SD | PR | CR | ORR | TTP | CB | PFS | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chura, 2007 | Bev 10 mg/kg q14d CP 50 mg qd po |
15 | Pretreated, recurrent |
3 (20%) |
6 (40%) |
2 (13.3%) |
53% | - | - | - | - |
|
| |||||||||||
| Gordinier, 2007 | Standard regimens | 18 | Pretreated, ovarian or primary peritoneal |
60% | 6.7% | - | - | - | - | 3.7 m | - |
| Thalidomide 200 mg qd | 18 | 53.8% | 5% | 3.8 m | |||||||
| None | 4 | ? | ? | ? | |||||||
|
| |||||||||||
| Downs, 2008 | Topotecan 1.25 mg/ m2days 1-5, q21d | 30 | Recurrent, epithelial, platinum refractory |
- | 17% | 30% | 47% | - | - | - | 19 m |
| Thalidomide 200 mg qd increasing to maximum tolerated Vs. |
Vs. | Vs. | Vs. | Vs. | Vs. | ||||||
| Topotecan 1.25 mg/ m2 days 1-5, q21d | 39 | - | 3% | 18% | 21% | - | - | - | 15 m | ||
|
| |||||||||||
| Garcia, 2008 | Bev 10 mg/kg q14d CP 50 mg qd po |
17 | Recurrent, platinum refractory |
- | 17 (24%) |
- | - | 7.2 m | - | 6 m (56%) |
16.9 m |
|
| |||||||||||
| Jurado, 2008 | Bev 10 mg/kg q14d CP 50 mg qd po |
9 | Recurrent, platinum refractory |
2 (22%) |
2 (22%) |
2 (22%) |
4 (44%) |
5.5 m | - | 6 m (33%) |
- |
|
| |||||||||||
| Hurteau, 2010 | Thalidomide 200 mg qd increasing to maximum tolerated or 400 mg vs Tamoxifen 20 mg qd po for 1 year |
138 | Stage III/IV, disease free after 1st line, | Closed early, interim analysis showed thalidomide was inferior to tamoxifen | |||||||
|
| |||||||||||
| Sanchez-Munoz, 2010 | Bev 10 mg/kg q14d CP 50 mg qd po |
38 | Pretreated, recurrent | 3 (8.1%) (6 w) |
12 (32.4%) |
3 (8.1%) |
- | - | - | 4.5 m | 10.7 m |
|
| |||||||||||
| Legge, 2011 | Carboplatin AUC5, q28d Celecoxib 400 mg qd |
45 | Pretreated, recurrent | 10 | 3 | 29% | - | - | 5 m | 13 m | |
|
| |||||||||||
| McGonigle, 2011 | Bev 10 mg/kg days 1, 13 q28d Topotecan 4 mg/ m2 days 1, 8, 15 q28d |
40 | Platinum resistant, ovarian / peritoneal / fallopian |
14 (35%) |
10 (25%) |
- | - | - | - | 7.8 m | 16.6 m |
|
| |||||||||||
| Ramasubbaiah, 2011 | Sorafenib 400 mg qd Topotecan 3.5 mg/ m2 days 1, 8, 15 q28d |
14 | Platinum resistant, |
14 (46.7%) |
5 (16.7%) |
- | - | - | - | - | - |
|
| |||||||||||
| Kucukoner, 2012 | Etoposide 50 mg qd po days 1-14 q28d | 51 | Platinum resistant, | 25.5% | 17.6% | 3.9 m | 16.4 m | ||||
|
| |||||||||||
| Barber, 2013 | Bev 10 mg/kg q14d CP 50 mg qd po |
66 | Pretreated, recurrent | 15 (22.7%) |
21 (31.8%) |
7 (10.6%) |
42.4% | 5 m responders) |
20 m responders) |
||
|
| |||||||||||
| Ferrandina, 2014 ® | CP 50 mg qd po | 54 | Platinum resistant/sensitive | - | 11 (20.4%) |
- | 20.4% | 4 m | 13 m | ||
|
| |||||||||||
| Bhattacharyya, 2015 | CP 50 mg qd po TMZ 20 mg bid days 1-14, q21d |
55 | Platinum resistant, | 24 | N/A | 44% | 5.9 m | 10.1 m | |||
|
| |||||||||||
| Roque, 2015 ® |
Ixabepilone 16-20 mg/ m2 days 1, 8, 15, q28d | 8/3 | Uterine/Ovarian-fallopian-peritoneal | - | - | - | 41.7% | - | - | 3.0 m/- | - |
| Vs | 9.6 m | ||||||||||
| Ixabepilone 16-20 mg/ m2 days 1, 8, 15, q28d Bev 10 mg/kg q14d |
16/33 | - | - | - | - | - | - | 6.5 m/ - | - | ||